Amicus Therapeutics, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$106.6M
Doctors Paid
640
Transactions
4,194
2024 Total
$3.5M
Payment Breakdown by Category
Research$104.9M (98.4%)
Consulting$817,496 (0.8%)
Travel$283,538 (0.3%)
Food & Beverage$29,050 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $104.9M | 2,701 | 98.4% |
| Consulting Fee | $817,496 | 307 | 0.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $409,354 | 48 | 0.4% |
| Travel and Lodging | $283,538 | 148 | 0.3% |
| Charitable Contribution | $96,500 | 8 | 0.1% |
| Food and Beverage | $29,050 | 954 | 0.0% |
| Space rental or facility fees (teaching hospital only) | $22,500 | 5 | 0.0% |
| Grant | $14,500 | 3 | 0.0% |
| Education | $1,074 | 20 | 0.0% |
Payments by Type
Research
$104.9M
2,701 transactions
General
$1.7M
1,493 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| PRE-CLINICAL STUDIES - UPENN/AMICUS RESEARCH COLLABORATION | $52.6M | 0 | 63 |
| PRE-CLINICAL GENE THERAPY / LYSOSOMAL STORAGE DISORDER | $29.5M | 0 | 108 |
| A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With LOPD | $6.1M | 0 | 707 |
| PROPEL Study - A Study Comparing ATB200/AT2221 With Alglucosidase/Placebo in Adult Subjects With LOPD | $4.6M | 1 | 384 |
| First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221 | $2.6M | 0 | 275 |
| AT2221-03 | $1.8M | 0 | 10 |
| Gene Therapy for Children With CLN3 Batten Disease | $1.4M | 0 | 53 |
| Gene Therapy for Children With Variant Late Infantile Neuronal Ceroid Lipofuscinosis 6 (vLINCL6) Disease | $782,541 | 0 | 35 |
| Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to <18 Years) | $674,651 | 0 | 533 |
| Functional Characterization and Reclassification of Pompe Disease | $432,000 | 0 | 1 |
| Functional characterization and reclassification of Pompe disease variants of uncertain significance (VUS) in carefully phenotyped patients: an approach towards high-throughput screening | $350,000 | 0 | 1 |
| ZIP Study - A Study to Evaluate the PK, Safety, Efficacy, and PD With ATB200/AT2221 in LOPD Subjects Aged 12 to <18 | $339,780 | 0 | 37 |
| Gene Therapy for Children With CLN6 Batten Disease | $274,215 | 0 | 8 |
| First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2263 | $237,980 | 0 | 2 |
| ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD | $205,173 | 0 | 28 |
| Open Label Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa | $204,620 | 0 | 36 |
| Developing a management approach for patients with the "late-onset" Pompe disease GAA variant identified by newborn screening: Towards better development and health | $202,144 | 0 | 3 |
| Developing a Management Approach for Patients With "Late-Onset" Pompe Disease | $202,144 | 0 | 2 |
| Tunneling Nanotube Associated Cross-Correction of Fabry cells in an In-vitro Model of Fabry Podocytopathy in Females | $186,629 | 0 | 2 |
| Tunneling Nanotube Associated Cross-Correction of Fabry cells in an In-vitro Model of Fabry Podocytopathy in Females. | $152,696 | 0 | 1 |
| First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2250 | $121,466 | 0 | 2 |
| A Study to Evaluate Migalastat in Fabry Subjects with Amenable GLA Variant and Renal Disease | $119,427 | 0 | 114 |
| First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2232 | $108,660 | 0 | 2 |
| First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2222 | $105,482 | 0 | 2 |
| Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) with Fabry Disease | $100,590 | 0 | 70 |
| Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) With Fabry Disease | $96,308 | 0 | 61 |
| IRB00101017-18-PAGe Study | $94,000 | 0 | 1 |
| First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2264 | $86,767 | 0 | 2 |
| First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2243 | $73,512 | 0 | 2 |
| First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2252 | $70,429 | 0 | 2 |
Payments by Medical Specialty
Top Paid Doctors — Page 8
| Doctor | Specialty | Location | Total | 2023 |
|---|---|---|---|---|
| Laurie Demmer, Md, MD | Pediatrics | Charlotte, NC | $55.31 | $0 |
| Dr. Michael Delong, M.d, M.D | Nephrology | Tucson, AZ | $54.79 | $0 |
| Robert Smith, D.o, D.O | Internal Medicine | Des Moines, IA | $53.89 | $0 |
| Unknown Provider | — | — | $53.68 | $0 |
| Sayed Tabatabai, M.d, M.D | Nephrology | Huntsville, TX | $53.60 | $0 |
| Matthew Schaefer, D.o, D.O | Internal Medicine | San Antonio, TX | $53.60 | $0 |
| Renee Levent, Rn, Bsn, Msn, Fnp-Bc, RN, BSN, MSN, FNP-BC | Registered Nurse | Bethesda, MD | $53.01 | $0 |
| Sandeep Jani, Md, Mph, MD, MPH | Cardiovascular Disease | Baltimore, MD | $53.01 | $0 |
| John Baker, Md, MD | Clinical Genetics (M.D.) | Phoenix, AZ | $51.02 | $0 |
| Dr. Richard Meador, M.d, M.D | Nephrology | Mobile, AL | $49.84 | $0 |
| Karee Morgan, Msn, MSN | Pediatrics | Nashville, TN | $49.68 | $0 |
| Jesse Flaxenburg, Md, MD | Nephrology | Colorado Springs, CO | $49.50 | $0 |
| Michael Ross, M.d., Ph.d, M.D., PH.D | Nephrology | Colorado Springs, CO | $49.50 | $0 |
| Dr. Mekdess Abebe, Md, MD | Nephrology | Roswell, NM | $49.23 | $0 |
| Matthew Taylor, Md, MD | Clinical Genetics (M.D.) | Aurora, CO | $49.00 | $0 |
| Muhammad Pervaiz, Md, MD | Clinical Genetics (M.D.) | Roswell, GA | $48.86 | $0 |
| Danielle Demarzo, Md, MD | Clinical Genetics (M.D.) | Oklahoma City, OK | $48.85 | $0 |
| Mark Lagatta, M.d, M.D | Nephrology | Winter Park, FL | $48.22 | $0 |
| Yeong-Hau Lien, Md, Ph.d, MD, PH.D | Nephrology | Tucson, AZ | $48.03 | $0 |
| Dr. Edgardo Laurel, M.d, M.D | Nephrology | Phoenix, AZ | $47.82 | $0 |
| Dr. William Golgert, M.d, M.D | Nephrology | Santa Barbara, CA | $47.78 | $0 |
| Dr. Manmeet Brar, Md, MD | Nephrology | Dover, DE | $47.59 | $0 |
| G Milan, M.d, M.D | Nephrology | Dover, DE | $47.59 | $0 |
| Dr. Daniel Hendrick, Md, MD | Internal Medicine | Amarillo, TX | $47.51 | $0 |
| Esther Iheukwumere, M.d, M.D | Nephrology | Paris, TX | $47.51 | $0 |
About Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc. has made $106.6M in payments to 640 healthcare providers, recorded across 4,194 transactions in the CMS Open Payments database. In 2024, the company paid $3.5M. The top product by payment volume is POMBILITI ($5.0M).
Payments were distributed across 59 medical specialties. The top specialty by payment amount is Internal Medicine ($396,853 to 77 doctors).
Payment categories include: Food & Beverage ($29,050), Consulting ($817,496), Research ($104.9M), Travel & Lodging ($283,538).
Amicus Therapeutics, Inc. is associated with 2 products in the CMS Open Payments database.